Donor-made memory T-cell therapy for hard-to-treat leukemia
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 1 study tests an immune-cell therapy made from a matched donor to treat relapsed or refractory CD19-positive leukemia. It may help patients who have limited options, especially those who cannot receive the standard donor-cell or self-made (autologous) CD19 CAR T-cell therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (the patient) are 21 years old or younger, and have CD19-positive leukemia confirmed by recent tests.
- Your leukemia must have come back or not responded to previous treatments, and you meet the trial’s timing rules for relapse or refractory disease.
- You must be in one of the study groups: Cohort A (you previously had a transplant using the selected donor) or Cohort B (you did not get that donor transplant).
- If you are in Cohort B, you must not be a good candidate for self-made (autologous) CD19 CAR T-cell therapy for reasons like failed prior attempts or medical unsuitability for collection.
- You must be well enough to tolerate treatment (including certain heart, lung, kidney, liver blood tests, and a minimum functional ability score).
- You must not have serious active infections, certain brain/spinal cord involvement with leukemia symptoms, or recent major complications after a prior transplant (if you’ve had one).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a two-step approach using donor immune cells to treat children with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to standard treatments. First, a donor's CD19-targeted cells are given to bridge to a stem cell transplant, followed by CD22-targeted cells to prevent relapse.
This early-phase trial studies whether a new type of immune therapy—CD19 CAR T cells made using the CliniMACS Prodigy system—is safe and feasible for children and young adults with relapsed or refractory CD19-positive ALL or non-Hodgkin lymphoma. It may be an option when standard treatments have not worked or the disease has come back.
This trial tests a special kind of immune cell therapy that targets two markers (CD19 and CD22) on leukemia cells. It is for children and teens whose leukemia has come back multiple times or has not responded to standard treatment.
This trial tests an immunotherapy called CAR T cells for leukemia that has come back or is hard to treat. It aims to use your own immune cells to fight the cancer.
This trial tests giving special immune cells (CAR T cells) after a half-matched stem cell transplant. It's for children and young adults with high-risk leukemia or lymphoma that has come back or not responded to treatment.
This early-phase trial tests CAR T-cells made to attack leukemia cells with specific markers (CD19 and CD22). It may help people with difficult-to-treat, relapsed, or high-risk acute lymphoblastic leukemia (ALL), especially when standard treatments haven’t worked well.
Hear when a new Acute Lymphoblastic Leukemia, in Relapse trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.